These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. The role of PPARs in the microvascular dysfunction in diabetes. Vinik A; Parson H; Ullal J Vascul Pharmacol; 2006 Jul; 45(1):54-64. PubMed ID: 16784897 [TBL] [Abstract][Full Text] [Related]
10. Muraglitazar, a novel dual (alpha/gamma) peroxisome proliferator-activated receptor activator, improves diabetes and other metabolic abnormalities and preserves beta-cell function in db/db mice. Harrity T; Farrelly D; Tieman A; Chu C; Kunselman L; Gu L; Ponticiello R; Cap M; Qu F; Shao C; Wang W; Zhang H; Fenderson W; Chen S; Devasthale P; Jeon Y; Seethala R; Yang WP; Ren J; Zhou M; Ryono D; Biller S; Mookhtiar KA; Wetterau J; Gregg R; Cheng PT; Hariharan N Diabetes; 2006 Jan; 55(1):240-8. PubMed ID: 16380499 [TBL] [Abstract][Full Text] [Related]
11. Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors. Fang F; Kang Z; Wong C Mol Nutr Food Res; 2010 Mar; 54(3):345-52. PubMed ID: 19866471 [TBL] [Abstract][Full Text] [Related]
12. Drug evaluation: rivoglitazone, a new oral therapy for the treatment of type 2 diabetes. Schimke K; Davis TM Curr Opin Investig Drugs; 2007 Apr; 8(4):338-44. PubMed ID: 17458185 [TBL] [Abstract][Full Text] [Related]
13. New therapeutic agents for the treatment of NIDDM. Kuehnle HF Exp Clin Endocrinol Diabetes; 1996; 104(2):93-101. PubMed ID: 8740931 [TBL] [Abstract][Full Text] [Related]
14. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Goldstein BJ Diabetes Technol Ther; 1999; 1(3):267-75. PubMed ID: 11475273 [TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological activity evaluation of a new class of 2,4-thiazolidinedione compounds as insulin enhancers. Huiying Z; Guangying C; Shiyang Z J Enzyme Inhib Med Chem; 2019 Dec; 34(1):981-989. PubMed ID: 31072232 [TBL] [Abstract][Full Text] [Related]
16. Selective PPAR agonists for the treatment of type 2 diabetes. Nehlin JO; Mogensen JP; Petterson I; Jeppesen L; Fleckner J; Wulff EM; Sauerberg P Ann N Y Acad Sci; 2006 May; 1067():448-53. PubMed ID: 16804025 [TBL] [Abstract][Full Text] [Related]
17. Editorial: Natural Compounds and Their Derivatives as a Source of Promising Drugs for Diabetes and Insulin Resistance. Mena Barreto Silva FR; Silva Frederico MJ Curr Drug Targets; 2017; 18(6):618. PubMed ID: 28831919 [No Abstract] [Full Text] [Related]
18. Pharmacological treatment of insulin resistance in obesity. Camejo G; Ljung B; Oakes N Nutr Metab Cardiovasc Dis; 2001 Aug; 11(4):275-84. PubMed ID: 11831112 [TBL] [Abstract][Full Text] [Related]
19. [Clinical difference between thiazolidinediones and biguanides]. Hotta N Nihon Rinsho; 2001 Nov; 59(11):2219-27. PubMed ID: 11712411 [TBL] [Abstract][Full Text] [Related]
20. Preventing the progression of diabetes mellitus. Reamy BV Am Fam Physician; 2005 Feb; 71(3):425. PubMed ID: 15712615 [No Abstract] [Full Text] [Related] [Next] [New Search]